Menu
← Oncology Approval Tracker
FDA DECISION ·
Nerlynx + capecitabine
neratinib + capecitabine · Puma Biotechnology
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with advanced or metastatic HER2-positive breast cancer after two or more HER2-directed regimens in the metastatic setting.
LAMPGEN ANALYSIS
Why it matters
Added an oral combination after several prior HER2-directed treatments.
What research teams should watch
Check prior metastatic regimens and provide a diarrhea prevention and escalation plan.
PRIMARY RECORDS